Figure S7 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Ursula A. Germann,Brinley F. Furey, William Markland,Russell R. Hoover,Alex M. Aronov,Jeffrey J. Roix, Michael Hale,Diane M. Boucher,David A. Sorrell,Gabriel Martínez-Botella,Matthew Fitzgibbon, Paul R. Shapiro, Michael J. Wick,Ramin Samadani,Kathryn Meshaw,Anna Groover,Gary DeCrescenzo,Mark Namchuk,Caroline M. Emery,Saurabh Saha,Dean J. Welschopenalex（2023）引用 0|浏览2暂无评分关键词Cancer,Cancer Therapy,MEK Inhibition,SignalingAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
